uPAR Controls Vasculogenic Mimicry Ability Expressed by Drug-Resistant Melanoma Cells.
Journal
Oncology research
ISSN: 1555-3906
Titre abrégé: Oncol Res
Pays: United States
ID NLM: 9208097
Informations de publication
Date de publication:
31 Jan 2022
31 Jan 2022
Historique:
pubmed:
29
7
2021
medline:
29
1
2022
entrez:
28
7
2021
Statut:
ppublish
Résumé
Malignant melanoma is a highly aggressive skin cancer characterized by an elevated grade of tumor cell plasticity. Such plasticity allows adaptation of melanoma cells to different hostile conditions and guarantees tumor survival and disease progression, including aggressive features such as drug resistance. Indeed, almost 50% of melanoma rapidly develop resistance to the BRAF
Identifiants
pubmed: 34315564
doi: 10.3727/096504021X16273798026651
pmc: PMC8790129
doi:
Substances chimiques
Pharmaceutical Preparations
0
Receptors, Urokinase Plasminogen Activator
0
Vemurafenib
207SMY3FQT
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
873-884Références
Mol Cancer. 2017 Mar 21;16(1):65
pubmed: 28320399
Clin Endocrinol (Oxf). 2012 Nov;77(5):780-6
pubmed: 22702340
J Mol Med (Berl). 2020 Oct;98(10):1431-1446
pubmed: 32803272
BMC Cancer. 2020 Jan 13;20(1):32
pubmed: 31931758
Cureus. 2021 May 18;13(5):e15087
pubmed: 34155457
J Leukoc Biol. 2001 Apr;69(4):522-30
pubmed: 11310837
Science. 2009 May 22;324(5930):1029-33
pubmed: 19460998
Crit Rev Oncol Hematol. 2002 Oct;44(1):17-27
pubmed: 12398997
Cells. 2020 Jan 28;9(2):
pubmed: 32012858
Ann Transl Med. 2017 Oct;5(19):387
pubmed: 29114545
Nat Rev Cancer. 2008 Jan;8(1):56-61
pubmed: 18059462
Breast Cancer Res. 2019 Aug 6;21(1):88
pubmed: 31387614
Pharmacol Ther. 2021 Jul;223:107805
pubmed: 33465401
J Cancer. 2019 Oct 18;10(25):6327-6340
pubmed: 31772665
Nat Med. 2006 Aug;12(8):925-32
pubmed: 16892036
J Biol Chem. 2001 Feb 16;276(7):4756-65
pubmed: 11085980
Nat Rev Cancer. 2011 Aug 11;11(9):671-7
pubmed: 21833026
Cancer Lett. 2017 Nov 1;408:43-54
pubmed: 28826720
Front Oncol. 2020 Feb 27;10:220
pubmed: 32175277
Mol Imaging Biol. 2011 Dec;13(6):1146-56
pubmed: 21181501
Nat Rev Cancer. 2017 Oct;17(10):577-593
pubmed: 28912578
Cancer Res. 2001 Sep 1;61(17):6322-7
pubmed: 11522618
Melanoma Res. 2018 Apr;28(2):96-104
pubmed: 29232304
EBioMedicine. 2019 Jan;39:194-206
pubmed: 30611716
Anticancer Res. 2014 Apr;34(4):1857-64
pubmed: 24692720
Clin Exp Metastasis. 2013 Dec;30(8):957-67
pubmed: 23784694
Eur J Cancer. 2013 Dec;49(18):3914-23
pubmed: 23992642
Exp Mol Pathol. 2015 Apr;98(2):136-44
pubmed: 25661888
Onco Targets Ther. 2018 Oct 17;11:7095-7107
pubmed: 30410366
Nature. 2002 Jun 27;417(6892):949-54
pubmed: 12068308
Sci Rep. 2020 Jul 14;10(1):11568
pubmed: 32665552
Am J Pathol. 1999 Sep;155(3):739-52
pubmed: 10487832
Clin Cancer Res. 2012 May 15;18(10):2726-32
pubmed: 22474319
Cell Prolif. 2019 May;52(3):e12600
pubmed: 30945361
Lab Invest. 2002 Aug;82(8):1031-43
pubmed: 12177242
Melanoma Res. 2017 Feb;27(1):8-16
pubmed: 27776018
Drugs. 2018 Apr;78(5):549-566
pubmed: 29488071
Carcinogenesis. 2015 Nov;36(11):1429-39
pubmed: 26424749